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INTRODUCTION 
 
Esophageal and gastric cancer are worldwide a serious health problem, which 
are very often lethal diseases with a case-fatality ratio of 84 and 75 percent 
respectively (Samm et al., 2017). 
During the last decades many efforts have been made in order to better define 
the nature of adenocarcinoma located at the esophago-gastric junction (AEG). In 
fact this tumor has been handled both as a gastric tumor or an esophageal tumor, 
without managing to reach an univocal classification leading to a standard of care 
for those patients.  
 
AEG definition and classification 
 
According to the UICC-2010 classification system - used to stage the patients 
cohort analyzed in this study - AEG is defined as a tumor whose epicenter is 
within 5 cm of the esophago-gastric junction (EGJ) and extending into the 
esophagus, while tumors with epicenter within 5 cm of the esophago-gastric 
junction extending into the stomach are to be considered gastric tumors (Siegel 
et al., 2012). 
A significant modification to this definition was introduced in the most recent 
UICC-2017 classification system (Brierley et al.): in fact tumors with their 
epicenters within 2 cm of the esophago-gastric junction (EGJ) and their 
extensions in to the esophagus should be classified using the esophageal 
scheme.  
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After many years of experience in the field of treatment of AEG, Siewert classified 
AEG into three different entities (Fig. 1): 
- AEG type I: tumors with their epicenter within 1-5 cm above EGJ  
- AEG type II: tumors with epicenter within 1 cm above and 2 cm below 
EGJ  
- AEG type III: tumors with their epicenter 2 cm below EGJ 
 
Fig. 1: Siewert Classification: the Z-line ist the passage between stratified 
squamous to columnar epithelium (0 cm) 
5 cm 
5 cm 
1 cm 
2 cm 
0 cm 
Type I 
Type II 
Type III 
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Crucial to the definition of true cardia carcinoma is the anatomical definition of the 
cardia, which is the passage between the two-layered esophageal muscular wall 
and the three-layered stomach muscular wall. This passage can be intra-
operatively detected as the passage between the tubular shaped esophagus, 
which does not present a serosa layer, and the stomach, which contrarily 
presents a serosa layer (Siewert et al.). 
This can be endoscopically detected as the end of the rugal folds of the gastric 
mucosa (Stein et al., 2000). 
The studies of Siewert´s group came to the conclusion that AEG I, or esophageal 
adenocarcinoma, should be treated as such, while AEG II and III, based on their 
biological behavior, should be classified as gastric cancer (Siewert et al., 1998, 
Siewert 2007).  
Huang and Hasegawa (Huang et al., 2010, Hasegawa et al., 2012) as well came 
to the conclusion that the gastric cancer classification better fits to AEG II and III 
than esophageal tumors classification. 
In contrast, Gertler et al concluded that neither the gastric nor the esophageal 
cancer classification properly suited AEG II/III (Gertler et al., 2011). Type II 
tumors in fact seem to have two distinct etiologies (esophageal adenocarcinoma 
originating from short or ultrashort Barrett´s esophagus and gastric 
adenocarcinoma caused by H.pylori infection and atrophic gastritis) (McColl et 
al., 2010, Derakjshan et al., 2008, Ren et al., 2009). 
According to this position, literature suggests that, due to its different biology, 
AEG should be considered as an entity separate from gastric cancer as well. 
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Clinical features 
 
Epidemiology 
 
True cardia carcinomas are characterized by a higher frequency of differentiated 
types, greater depth of invasion, higher incidence of metastasis and poorer 
prognosis (McColl et al., 2010, Tajima et al., 2001). 
The incidence of AEG is significantly increasing in the western countries, being at 
present the 2nd most common cause of cancer-related death (Song et al., 2014). 
Lot has been researched in understanding the carcinogenesis of this tumor and 
identifying its risk factors in order to do prevention and early diagnosis (McColl et 
al., 2010, Tajima et al., 2001). 
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Esophageal carcinoma (Müller et al., 2018/19) 
Incidence: 
Incidence of esophageal carcinoma is 8/100000/year, with a geographical 
difference which sees a higher incidence in Japan and England, maybe due to a 
higher consume of spicy food and tea. Male subjects seem to be more exposed 
(M/F 5/1) and the highest risk age is between 50 and 60 years. 
Pathology: 
The majority of esophageal carcinomas are adenocarcinomas (60-80%), 
especially in the distal segment and cardia, 20-40% are squamous-cell 
carcinomas, located predominantly in the upper esophagus and usually have a 
worse prognosis. 
Undifferentiated carcinomas and melanomas can also be rarely found in the 
esophagus. 
Due to the absence of a serosa layer, the local spread of these tumors is early 
and massive; the first route of spreading is through the periesophageal, 
mediastinal and perigastric lymph vessels for lower thoracic carcinomas, whilst 
the upper thoracic and cervical tumors spread through periesophageal and 
cervical lymph vessels. 
Hematogenic metastases develop by migration through the gastric veins to the 
liver via the portal system (lower tumors), and to the lungs via the azygos vein 
and the upper cava vein from upper tumors. 
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Stomach carcinoma (Müller et al., 2018/19) 
Incidence: 
Incidence of stomach carcinoma is 19/100000 per year. Its incidence in 
Germany, like in other industrialized countries, is decreasing, maybe due to 
healthier alimentary habits. Male subjects seem to be slightly more exposed (M/F 
1,5/1) and the highest risk age is above 60 years. 
Pathology: 
90% of these tumours are adenocarcinomas. They can be classified in papillar, 
tubular, mucinous, and signet ring cell differentiated and poorly cohesive type. 
The remaining 10% are squamous cell carcinomas, adenosquamous and 
undifferentiated. 
The histological characteristics of stomach adenocarcinoma are often classified 
according to Lauren Classification, which differentiates between intestinal, diffuse 
and mixed type. The three entities have a different biological behavior, with 
repercussions on the therapeutic options. 
- The intestinal type, present mostly as polipoid formed with a majority of 
glands and has a better prognosis (tubular, papillar and mucinous). 
- The diffuse type presents an infiltrative growth into the mucosa and has a 
worse prognosis (signet ring cell type, poorly cohesive).  
- Mixed type 
The most frequent localization is antrum and pylorum (50-80%), the cardia and 
the smaller curvature are involved in 10-25% of the cases. 90% are solitary 
carcinomas, 10% of patients show multiple localizations. 
The local spread of these tumors can involve the nearest organs as liver, 
pancreas and spleen, colon, diaphragm, peritoneum and mostly the great 
omentum. Lymphogenic metastases develop in the periesophageal, mediastinal 
and perigastric lymph nodes for cardia carcinomas, whilst antrum tumours 
infiltrate the perigastric lymph vessels along the bigger and smaller curves. 
Hematogenic metastases develop mostly in the liver.  
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Etiology and Risk Factors of AEG 
 
Carcinogenesis of AEG, as for other gastrointestinal tumors, seems to be related 
to chronic inflammation. In fact inflammation represents a continuous damage of 
the tissue, stimulating the repair and re-growth systems. 
Thus the importance in AEG carcinogenesis, diagnosis and cure, of a number of 
risk factors related to an increased inflammation of the cardia region. 
These are gastro-esophageal reflux disease (GERD) (Zehetner et al., 2010, 
Lagergren et al., 1999), Barrett´s esophagus (BE) (Morrow et al., 2014), obesity 
(Lagergren et al., 1999), tobacco smoking (Lagergren et al., 2000), shorter 
dinner-to-bed time (Song et al., 2014) and H-pylori infection (Siveke et al., 2013). 
 
- GERD and Barrett´s esophagus: BE is a change of the normal stratified 
squamous epithelium of the distal esophagus to metaplastic columnar 
epithelium of mucous-secreting goblet cells, caused by chronic GERD 
(Fitzgerald et al., 2013). Risk factor for progression form BE to AEG are 
esophagitis, long segment Barrett, dysplasia (Kastelein et al., 2014) 
- It is proved that obesity is associated with an increased risk of colon 
cancer, postmenopausal breast cancer, endometrial cancer, renal cell 
cancer and adenocarcinoma of the esophagus (Boeing et al., 2013). 
Recent studies and meta-analyses showed a higher risk for AEG in obese 
subjects as well (Chen et al., 2013, Turati et al., 2012). The potential 
mechanisms throughout which obesity may have an influence on 
carcinogenesis in AEG are various. One is the increased intraabdominal 
pressure caused by overweight (Jung et al., 2013) promoting GERD and 
thus Barrett´s esophagus and therefore AEG (Wu et al., 2003). Another 
way obesity could have an influence on AEG development is through the 
induction of hyperinsulinemia. High levels of insulin-like growth factors, 
adipokine imbalance and estrogen might increase the cell proliferation and 
impair the apoptotic process (Lindblad et al., 2005, Mcmilian et al., 2006). 
 Page 12 
 
Furthermore obesity has been proved to evoke a proinflammatory state 
inducing high levels of proinflammatory cytokines. 
- Tobacco smoking: current smoking status appeared to be associated to 
a moderately increased risk of both esophageal and gastric cancer, cardia 
adenocarcinoma and esophageal squamous-cell carcinoma. 
In a recent study (Cook et al., 2010) a strong association between 
cigarette smoking and esophagogastric junctional adenocarcinoma was 
demonstrated (OR = 2.18, 95% CI = 1.84 to 2.58). In addition, there was a 
strong dose–response association between pack-years of cigarette 
smoking and outcome (P < .001). Compared with current smokers, longer 
smoking cessation was associated with a decreased risk of all 
adenocarcinoma after adjusting for pack-years (<10 years of smoking 
cessation: OR = 0.82, 95% CI = 0.60 to 1.13; and ≥10 years of smoking 
cessation: OR = 0.71, 95% CI = 0.56 to 0.89). Sex-specific summary odds 
ratios were similar. 
Among ex-smokers the risk of gastric cardia adenocarcinoma was found 
higher as well (Lagergren et al., 2000). 
 
- A study published in 2014 (Song et al., 2014) examinated the impact of 
dinner-to-bed time on incidence of AEG, suggesting that a shorter 
dinner-to-bed time increases the risk of AEG. Reversely post-dinner walk 
seems to decrease it. Some studies showed an increased incidence of 
GERD in subjects who go to sleep just after having dinner. An explanation 
of these results could be that the gastric distention after dinner could 
cause an increased transient relaxation of the lower esophageal sphincter 
(Dodds e t al., 1982). In several studies a night-time acid reflux was 
detected through 24-hours pH-metry (Dickman et al., 2007). This seems to 
be associated with more severe esophageal injuries, probably because of 
the long-lasting symptom characteristics (Lagergren et al., 1999). On the 
other side it is known that regular physical activity protects against AEG 
(Singh et al., 2013, Abioye et al., 2015) as much as against cancer of the 
colon, breast and endometrium (Colditz et al., 2006). This seems to be 
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due to a lower incidence of obesity and its carcinogenetic mechanisms 
(described above), as much as to a very likely better health consciousness 
in the subjects having physical activity. Besides that, post-dinner walk 
seems to reduce GERD symptoms by increasing gastric emptying rate 
(Avidan et al., 2001). 
 
- H-pylori infection is a spiral-shaped bacterium living in the mucus layer of 
the stomach. It secrates urease, an enzyme able to convert urea to 
ammonia, neutralizing the acidity of the stomach. Furthermore it can 
reduce the capacity of the local immune response to attack the bacterium 
(Polk et al., 2010, Busuttil et al., 2009). Although it is estimated that H. 
pylori is harbored in about two thirds of the population, with a higher 
incidence in developing countries and children, it does not cause illness in 
any of its hosts. Nevertheless it is accepted as a risk factor for peptic ulcer 
disease and for gastric cancer (mucosa-associated lymphoid tissue –
MALT- and adenocarcinoma of the cardia). Its role in development of 
esophageal adenocarcinoma is more controversial and related to the fact 
that stomach colonization from H. pylori is eventually related to a reduced 
risk of adenocarcinoma. 
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Symptoms 
 
The symptoms related to AEG are very unspecific and therefore in most of the 
cases the diagnosis is made when the disease is already in an advanced stage. 
In fact, only 50% of the tumors are eligible for curative resections. For this reason 
screening with gastroscopy has a crucial role in early diagnosis. 
The more common symptoms are: 
 
- Weight lost due to reduced caloric intake as a result of abdominal pain, 
nausea and dysphagia (Wanebo et al., 1993). 
 
- Gastrointestinal Bleeding (occult or overt) with consecutive anemia 
(Wanebo et al., 1993). 
- Pseudoacalasia due to the infiltration of the Auerbach´s plexus as a result 
of the local extension near the EGJ (Kahrilas et al., 1987). 
 
- A left supraclavicular adenopathy (Virchow´s node) or a periumbilical 
nodule (St. Mary Josephs´node) may be detected as a sign of nodal 
infiltration (Morgenstern 1979, Pieslor et al., 1986). 
 
- Signs of tumor spread (Gilliland et al., 1992, Winne et al., 1965) may be 
ascites form peritoneal carcinosis, involvement of the ovaries 
(Krukenberg´s tumors), palpable lymphadenopathies left supraclavicular or 
axillar, and palpable liver tumors. 
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Diagnosis and staging 
 
The diagnostic tools used in to detect and assess the stage of AEG are the 
following: 
 Endoscopy 
 Endosonography 
 Barium swallow 
 CT Scan and MRI 
 PET-CT 
 Laparoscopy 
 
Endoscopy: 
 
The gold standard for the diagnosis of AEG is conventional upper GI endoscopy 
(di Pietro et al.). In fact during this procedure it is possible not only to detect the 
lesion (Fig. 2), but also to take biopsies (Fig. 3) and to precisely describe the 
localization and extension. Correct assessment of AEG tumors includes the 
documentation of its dimension (tumor length, extent of circumferential 
involvement, degree of obstruction), the distance from teeth to the EGJ and the 
evidence of Barrett´s esophagus. 
The necessity to increase the early diagnosis inevitably leads to the topic of 
screening programs: in a recent meta-analysis published in the UK (Graham et 
al., 1982) it is stated that screening should be recommended only for multiple risk 
factors, and that the threshold for screening should be lowered in the presence of 
positive family history. 
The same study also indicates conventional upper GI endoscopy as the gold 
standard for screening of oesophageal malignancies. This is due to the very high 
accuracy, with a sensitivity between 92 and 96,6%, and a specificity between 84 
and 94,6%. 
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Disadvantages of this examination are its costs, the need of sedation and 
possible complications (upper GI perforation and bleeding). 
 
Fig. 2: endoscopic image of a cardia adenocarcinoma 
 
Fig. 3: histopathologic section of a cardia adenocarcinoma 
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Radiology: 
 
Other less invasive examinations as barium swallow (Dooley et al., 1984) may as 
well detect AEG (Fig.4) but with a lower sensitivity and without the possibility of 
such a precise and complete description of the tumor. Furthermore the capacity 
to perform histology makes endoscopy the first choice examination both in 
screening and diagnosis of AEG. 
Because of the presence of a better diagnostic option such as gastroscopy, 
barium swallow is rarely used nowdays. 
 
Fig. 4: barium swallow showing a stenosis of the cardia 
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Staging 
 
After histological confirmation of AEG, it is necessary to perform an exact staging 
of the disease in order to assess the stage and therefore the proper treatment 
strategy. 
The staging system for AEG is based on the local tumor extension measured as 
the depth of the wall invasion (T), the number of involved nodes (N) and the 
presence of metastasis (M). 
In the Tab. 1 updated staging systems of esophagus and esofago-gatric junction 
carcinoma are described (Brierley). 
Oesophagus 8th edition 
TNM definition 
Tis Carcinoma in situ/high grade displasia 
T1a lamina propria or muscularis mucosa 
T1b Submucosa 
T2 muscularis propria 
T3 Adventitia 
T4a pleura, pericardium, diaphragm 
T4b aorta, vetebral body, trachea 
N0 no lymph nodes 
N1 1 to 2 regional lymph nodes 
N2 3 to 6 lymph nodes 
N3 7 or more lymph nodes 
M1 distant metastasis 
Grading 
Gx Grade cannot be assessed—stage grouping as G1 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 
Anatomic stage/prognostic groups  
I T1 N0, N1 M0 
 
  
II T2 N0, N1 M0 
 
  
  T3 N0 M0 
 
  
IVA T4a, b N0, N1, N2 M0 
 
  
IVA  Any T N3 M0 
 
  
IVB Any T Any N M1 
 
  
 
Tab. 1: Esophagus carcinoma including EGJ Staging – UICC 8  
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Endosonography (endoscopic ultrasound): 
 
The gold standard in order to assess the T and N stage is endosonography 
(Barbour et al., 2012) of the upper GI tract.  
Through the combination of endoscopy and ultrasonography (Fig. 5)  it is 
possible to applicate the  ultrasound probe on the very surface of the tumor, 
making it possible to describe the aspect of the layers of the hollow organ (T 
staging) as much as the morphological aspects of the local lymph nodes (N 
staging). 
  
 
Fig. 5: Endosonographic image of a cardia tumor 
 
This examination has an overall accuracy for T and N staging of 80 to 90 percent, 
being able to evaluate both perigastric and mediastinal lymph nodes (Barbour et 
al., 2012).   
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CT and MRI  
 
CT scan (Fig. 6) of the thorax and the abdomen is a widely used staging 
examination, particularly with the aim of detecting liver and lung metastasis, as 
well as lymph nodes in the distance (intraabdominal, cervical or supraclavicular, 
etc.). Unfortunately the sensitivity of this examination is not particularly high.  
MRI can also be used to assess the T and N stage of EJA. 
 
A study recently published in Italy (Giganti et al., 2016), summarizes the accuracy 
of MR, CT and EUS as follows: 
  
Preoperative 
Staging 
MR CT EUS 
MR vs CT MR vs EUS CT vs EUS 
p-value p-value p-value 
T   
Sensitivity 67 83 100 0,56 0,16 0,32 
Specificity 92 63 67 0,16 0,08 0,56 
Accuracy 83 78 78 1 1 1 
Positive 
predictive value 
80 62 60 0,68 0,12 0,29 
Negative 
predictive value 
83 90 100 0,68 0,12 0,29 
N   
Sensitivity 100 75 100 0,31 1 0,31 
Specificity 57 57 36 1 0,08 0,08 
Accuracy 66 61 50 1 0,25 0,61 
Positive 
predictive value 
40 33 31 0,29 1 0,29 
Negative 
predictive value 
100 89 100 0,29 1 0,29 
 
Tab. 2: Performance characteristics of MR, multidetector CT and endosopic 
ultrasonography for local invasion (T) and nodal infiltration (N). 
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Fig. 6: CT image of a cardia carcinoma 
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PET-CT: 
 
In order to achieve a better interpretation of pathological nodes or potential 
distant metastases detected with a CT scan, it is possible to perform Positron 
emission tomography–computed tomography (PET-CT) (Fig. 7), which can 
provide information on the metabolic activity of the target tissue (Erhunmwunsee 
et al., 2015). PET-CT is a nuclear medicine technique which combines, in a 
single gantry, a positron emission tomography (PET) scanner and a traditional 
CT scanner. It conjugates the capacity of CT to perform a rather precise slice 
imaging of the whole body, with the possibility to detect the level of metabolic 
activity through the injection of a contrast medium radiopharmaceuticals as 
fluorodeoxyglucose (FDG) and Fluroine-18, which will be concentrated in more 
metabolic active cells, such as tumor cells. (Townsend 2008) 
A difficulty in the interpretation of these images is given from inflammation activity 
(like postoperative or infections for example), which can falsely be interpreted as 
tumor tissue. 
Another limitation of this examination is due to the very high costs of transporting 
and stocking the contrast. 
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Fig. 7: PET/CT image of a cardia adenocarcinoma 
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Explorative laparoscopy: 
 
To better assess the stage of locally advanced AEG, an explorative laparoscopy 
is recommended if a peritoneal carcinosis is suspected (Mortensen et al., 2012). 
In these cases a laparoscopy will allow to take direct vision of the liver, ovaries 
and peritoneal surface (Fig. 8a). During this procedure it is also possible to 
perform a histological or cytological sampling of the tissues.  
The result of this examination has a crucial role in chosing neoadjuvant or 
palliative systemic treatment. In fact patient with a local or locally advanced tumor 
will go for a neoadjuvant treatment, while patients with histologically 
demonstrated metastatic spread are only for non-curative treatment options. 
The elegibility to HiPEC is assessed through the peritoneal cancer index (PCI, in 
Fig 8b) . For this purpose, the peritoneal cavity is divided in 13 well-defined 
regions (see figure 8b). In each of the 13 regions, the size of the largest 
tumor nodule is measured. If no tumor is visualized, a score of “0” is given to that 
region. If the largest tumor nodule is smaller than 0.5 cm, the score is “1”. For 
tumors measuring between 0.5 cm and 5 cm, the score is “2”. For lesions larger 
than 5 cm, the score is “3”. If there is layering or a confluence of multiple small 
tumor nodules, the score is “3”. The PCI is calculated by adding the scores of all 
13 regions together with a maximum score of 39 (13×3). (Gilly et al., 2006). 
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Fig. 8a: Peritoneal carcinosis detected through laparoscopy 
 
Fig. 8b: peritoneal cancer index 
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Treatment 
 
Chemotherapy 
Nowadays multimodality treatment, either consisting of perioperative platinum-
based chemotherapy (CT) or neoadjuvant radiochemotherapy followed by 
surgery is the standard of care in Western centers for locally advanced tumors 
(Samm et al., 2017, Cunningham et al., van Hagen et al., 2013, Shapiro et al., 
2015).  
Recent studies (Samm et al., 2017, Siewert, 2006, Huang et al., 2011) 
demonstrated that histopathologic response to chemotherapy is an independent 
prognostic factor. 
 
- MAGIC-trial 
A landmark trial on this topic, the MAGIC trial (Cunningham et al.), showed a 
clear down-staging in patients with locally advanced AEG treated preoperatively 
with three cycles of epirubicin, cisplatin and 5-fluorouracil (ECF regimen) 
compared to non treated patients. Furthermore the postoperative complications 
and mortality were not higher in the chemotherapy group than in controls.  
5-year survival rate was 36% for patients receiving perioperative chemotherapy, 
vs 23% in the control group.  
A major weakness of the MAGIC trial is the fact that most of the patients 
underwent an inappropriate lymphadenectomy (only 43% of resected patients 
received a D2 lymphadenectomy), suggesting that the perioperative 
administration of chemotherapy might compensate the inadequate surgical 
treatment (Ychou et al., 2011). 
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- ACCORD-trial 
Another study comparing a perioperative treatment to surgery demontrated that 
R0 resection rates in patients who underwent a preoperative regimen with 
cisplatin anf 5-fluorouracil were significantly higher than in the non-chemotherapy 
cohort (84% vs 73%). Also in this case the 5 year survival rate was higher in 
patients receiving perioperative systemic chemotherapy (38% vs. 24%). 
(Schumacher et al., 2010). 
 
- EORTC-trial 
Another confirmation of the benefit of a perioperative chemotherapy comes from 
Schumacher et al. (Schumacher et al., 2010). 
After a neoadjuvant regimen with cisplatin, 5 fluorouracil and folinic acid (PLF) a 
higher rate of R0 resection was detected, as much as a downstaging of the 
tumor. 
 
- FLOT  
A recent work from Sprinfield et al. compared four different perioperative 
regimens, two duplets (cisplatin and 5 fluorouracil or oxaliplatin and 5 fluorouracil) 
and two triplets (epirubicin, platinum and 5 fluorouracol or taxane, platinum and 5 
fluorouracil). The last one seemed to achieve a higher rate of complete 
regression. (Springfeld et al., 2015). 
Another study published in 2016 (Al-Batran et al., 2016) reported findings from 
the phase 2 part of the phase 2/3 FLOT4 trial, comparing histopathological 
regression in patients treated with a docetaxel-based triplet chemotherapy versus 
an anthracycline-based triplet chemotherapy before surgical resection. This study 
suggests that FLOT4 is perioperative feasible to administer, and might represent 
a more effective option for patients with locally advanced, resectable gastric or 
gastro-eosophageal junction adenocarcinoma.  
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Radiochemotherapy: 
Though the combination of perioperative chemotherapy combined with a 
preoperative administration of radiation is increasingly considered as the 
standard for esophageal and esophagogastric adenocarcinoma (Reynolds et al., 
2017). 
 
- CROSS-trial 
The CROSS-trial compared the outcomes of patients undergoing 
chemoradiotherapy  (paclitaxel, carboplatin and 41,4 Gy in 23 fractions) vs. 
surgery only, showing a 47% 5 years survival in the multimodal arm vs. 34% in 
surgery only group. The rate of R0 resection was also clearly higher in the 
systemically treated patients (92% vs. 69%).(Shapiro et al., 2015, Van Hagen et 
al., 2012, Stahl et al., 2009) 
 
- POET-trial 
The POET-trial compared the outcomes of two cohorts undergoing a 
perioperative regimen of cisplatin, leucovorin and FU vs. cysplatin, etoposide and 
a preoperative administration of 30 Gy radiation in 15 fractions. 3 year survival 
was 47,4% in the chemoradiotherapy arm vs. 27,7% in the chemotherapy group. 
Beside that the pathological complete response rate was 15,6% vs. 2%  
respectively) (Stahl et al., 2009). 
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Resection 
Though the important impact of systemic treatment in the battle against AEG, the 
removal of the primary tumor-mass is still the mainstay of the multimodal 
treatment. 
Being the surgical resection an aggressive procedure with severe impact on the 
quality of life of patients and with potentially severe complications, it is mandatory 
to always consider the possibility to achieve an R0 resection through the least 
possible invasive procedure. In case of early cancers (T1a and T1b SM1) 
endoscopic mucosectomy associated to a strict follow-up is a valid option (Osumi 
et al., 2016, Tokyo National Cancer Center). 
 
Endoscopic mucosectomy: 
The endoscopic resection of the mucosa is a minimally invasive procedure that 
allows to completely remove tumor when the latter is confined to the most 
superficial layer of the mucosa. This procedure can be considered curative only 
after the pathological assessment detects (Japanese gastric cancer treatment 
guidelines):  
- A T1a tumor differentiated type adenocarcinoma, well-to-moderately 
differentiated with no ulceration 
- A T1a tumor with a maximum diameter of >= 30 mm, differentiated type, 
with no ulceration 
- A T1a tumor with a maximum diameter of >= 20 mm, poorly differentiated 
or signetringcell, no ulceration 
- A T1b /SM1) with a maximum diameter of >= 30 mm, differentiated. 
 
Tumors with more aggressive aspects (dimension, depth of invasion, grading or 
ulceration) will need further surgical resection to allow the assessment of N status 
and be curative in case of nodal involvment. 
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Surgical resection:  
Though it is generally accepted that surgery is the mainstay of therapy for AEG, it 
is still matter of discussion which resection technique should be adopted as gold 
standard. 
At present the two most frequently used approaches are esophageal resection 
with proximal gastrectomy and gastric-tube reconstruction via a right or left 
thoraco-abdominal approach (RTA/LTA) (Shapiro et al., 2015, Yamashita et al., 
2011) or alternatively an extended gastrectomy through an abdominal-transhiatal 
approach (TH) (Yamashita et al., 2011, Barbour et al., 2007, Leers et al., 2009, 
Siewert et al., 2000, Sasako et al., 2006). 
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Esophageal resection with proximal gastrectomy and gastric-tube reconstruction 
via a right or left thoraco-abdominal approach (RTA/LTA) 
 
A partial gastrectomy is performed through an abdominal access (laparotomy or 
laparoscopy) in order to prepare the gastric pull up. In this phase of the operation 
a perigastric lymphadenectomy is also performed. Afterwards esophagectomy 
and mediastinal lymphadenectomy are performed through a right thoracotomy. 
The operation is completed by pulling up the remain of the stomach which has 
been shaped as a tube along the greater curve and is connected to what is left of 
the esophagus high in the chest (at the level of the Azygos vein). 
 
 
Fig. 9: Esophageal resection with proximal gastrectomy and gastric-tube 
reconstruction via a right or left thoraco-abdominal approach (RTA) 
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Extended gastrectomy through an abdominal-transhiatal approach (TH) 
 
A total gastrectomy is performed through an open abdominal access 
(laparotomy), A D2 lymphadenectomy (a description of the lymphadenectomy will 
follow in the next paragraph) is also performed. In this case esophagectomy and  
lymphadenectomy in the lower mediastinum are performed through the hiatus. 
The operation is completed performing an Roux-Y anastomosis between the 
jejunum about 70 cm from duodenum, and the thoracic esophagus. The 
operation is completed by performing a suture between the first part of the 
jejunum about 50 cm after the esophago-jejunum anastomosis in order to ensure 
the proper flow of the bile and the pancreatic juice. 
 
Fig. 10: Extended gastrectomy through an abdominal-transhiatal approach (TH) 
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Arguments in favor of the more invasive thoraco-abdominal approach are the 
possibility of achieving greater oral margins and more extended mediastinal 
lymph node dissection. Conversely TH is a less invasive procedure, additionally 
allowing for more extended intra-abdominal lymphadenectomy along the greater 
curvature which needs to be left unattended in RTA/LTA in order not to 
compromise the blood-supply of the gastric-tube. However, the anastomosis in 
TH is technically more challenging, due to the often high extension into the 
mediastinum. The effective role of these factors is still to be elucidated. 
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The role of lymph node dissection (Yamashita et al., 2011) 
Despite an abundance of publications about lymphadenectomy in surgery of true 
cardia carcinomas, no gold standard has been established. At present it is usual 
to perform a D2 dissection when performing a gastrectomy (including therefore 
the stations 1 to 12 (Fig.11), and the lower mediastinal stations. When performing 
a thoracic approach the abdominal lymph nodes dissection will be less extensive, 
but the mediastinal lymphnodes up to the bronchial bifurcation will be removed. 
 
 
Fig. 11: Gastric lymphnodal stations: 
1- Right cardiac 
2- Left cardiac 
3- Lesser curvature 
4- Greater curvature 
5- Suprapyloric 
6- Infrapyloric 
7- Left gastric artery 
8- Common heparic artery 
9- Celiac axis 
10- Splenic hilus 
11- Splenic artery 
12- Hepatoduodena ligament  
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Minimally invasive approach 
 
With the development of robotic surgical technology and equipment, minimal 
invasive resection for EJA has been widly used. 
In a study recently published (Zang et al., 2018), it is observed that in case of 
esophagectomies, the mediastinal and abdominal lymphadenectomy can be 
conducted by thoracoscopy and laparoscopy respectively. After that a gastric 
tube is placed and the reconstruction is performed in the mediastinum. For TH, 
the whole procedure is accessed by laparoscopy and the lower mediastinum is 
accessed transhiatally. After lymphadenectomy the anastomosis can be 
performed  laparoscopic-assisted or totally laparoscopic. As for Siewert type III, 
both circular and linear stapler can be used to perform reconstruction. 
A study published in 2019 (Yoontaek e tal., 2019) compared the surgical and 
oncological outcome of 108 patients undergoing TH for true cardia 
adenocarcinoma (37 laparoscopic and 71 open), showing that the laparoscopic 
approach is feasible and safe, it gives advantages in terms of a better 
visualisation of the surgical field, of lesser postoeprative pain and blood loss, as 
much as a lower infection rate. On top oft hat it showed short- and longterm 
oncological result siminalr tot he open approach. 
A recently pubished study (van den Berg et al., 2018) comparing the outcomes of 
combined laparoscopic-thoracoscopic approach for RTA with fully open surgery, 
showed that the minimally invasive approach is as safe as the open, presenting 
less blood loss without affecting the oncological accuracy.  
It is likely to believe that the use of a minimally invasive approach in treatment of 
true cardia adenocarcinoma, is destined to increase in the clinical routine (Wang 
et al.). 
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AIM OF THE STUDY 
 
Although the clinical research throughout the last decades focused on defining a 
gold standard for AEG treatment, it is still unclear which surgical procedure 
between RTA and TH should be preferred.  
Aim of our analysis is to analyze the outcome of patients treated in our center in 
order to evaluate if any of the two surgical approaches is superior regarding 
oncological outcome, R0 resection rate and survival. 
 
Objectives of our analysis are: 
 
Oncological outcome 
To define the difference in the rates of R0 resection achieved through the two 
different techniques, as much as the impact of the surgical approach on the 
lymph nodes dissection. 
Perioperative morbidity and mortality 
To define which surgical approach is related to a lower complication rate and 
better postoperative outcome. 
Survival 
To define if there is a statistical significant difference in postoperative survival 
after the two different resection techniques. 
Recurrence 
To investigate if the surgical approach has an impact on future recurrence and 
their location. 
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PATIENTS AND METHODS 
 
Data Collection 
Tumor- and patient-related data of all patients undergoing curative RTA or TH for 
Siewert type II AEG at the Klinikum Rechts der Isar, Munich, Germany, between 
2000 and 2013 were extracted from a prospectively documented esophageal and 
gastric-cancer data base.  
 
Inclusion criteria 
All patients with histologically proven adenocarcinoma of the esophago-gastric 
junction (AEG II after Siewert endoscopic classification) and with a potentially 
resectable disease were enrolled. 
 
Exclusion criteria 
Patients with a secondary malignancy, systemic metastases (M1) or R2 resection 
were excluded from the analysis. 
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Staging 
Patients were staged by CT of the thorax/abdomen/pelvis and esophago-gastro-
duodenoscopy (EGD), including an endoscopic ultrasonography of the tumor 
(EUS) for assessment of the depth of invasion (uT). 
- tumor length 
- extent of circumferential involvement 
- degree of obstruction 
- distance from teeth 
- evidence of Barrett´s esophagus. 
Since the patients were recruited between 2000 and 2013, we used the 2010 
UICC TNM staging system (Sobin et al., 2011). 
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Oesophagus 7th edition 
TNM definition 
Tis Carcinoma in situ/high grad displasia 
T1a lamina propria or muscularis mucosa 
T1b Submucosa 
T2 muscularis propria 
T3 Adventitia 
T4a pleura, pericardium, diaphragm 
T4b aorta, vetebral body, trachea 
N0 no lymph nodes 
N1 1 to 2 regional lymph nodes 
N2 3 to 6 lymph nodes 
N3 more than 6 lymph nodes 
M1 distant metastasis 
Grading 
Gx Grade cannot be assessed—stage grouping as G1 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 
Anatomic stage/prognostic groups  
IA T1 N0 M0 G1, G2, Gx   
IB T1 N0 M0 G3   
  T2 N0 M0 G1, G2, Gx   
IIA T2 N0 M0 G3   
IIB T1,T2 N1 M0 Any G   
  T3 N0 M0 Any G   
IIIA T1,T2 N2 M0 Any G   
  T3 N1 M0 Any G   
  T4a N0 M0 Any G   
IIIB T3 N2 M0 Any G   
IIIC T4a N1, N2 M0 Any G   
  T4b Any N M0 Any G   
  AnyT N3 M0 Any G   
IV AnyT Any N M1 Any G   
 
Tab. 3a: Esophagus carcinoma Staging (2010 UICC) 
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Stomach 7th edition 
TNM definition 
Tis Carcinoma in situ/high grad displasia 
T1 lamina propria or muscularis mucosa 
T1b Submucosa 
T2 muscularis propria 
T3 Adventitia 
T4a visceral peritoneum 
T4b adjacent structures 
N0 no lymph nodes 
N1 1 to 2 regional lymph nodes 
N2 3 to 6 lymph nodes 
N3a 7 to 15 lymph nodes 
N3b more than 15 
M1 distant metastasis 
Anatomic stage/prognostic groups  
IA T1 N0 M0 
 
  
IB T1, T2 N0 M0 
 
  
IIA T1 N2 M0 
 
  
  T2 N1 M0 
 
  
  T3 N0 M0 
 
  
IIB T1 N3 M0 
 
  
  T2 N2 M0 
 
  
  T3 N1 M0 
 
  
  T4a N0 M0 
 
  
IIIA T2 N3 M0 
 
  
  T3 N2 M0 
 
  
  T4a N1 M0 
 
  
IIIB T3 N3 M0 
 
  
  T4a N2 M0 
 
  
  T4b N1 M0 
 
  
  T4b N0 M0 
 
  
IIIC T4a N3 M0 
 
  
  T4b N2, N3 M0 
 
  
IV AnyT Any N M1     
 
Tab. 3b: Stomach carcinoma Staging (2010 UICC) 
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Treatment 
 
All cases were discussed in a multidisciplinary tumor conference prior to the 
beginning of treatment and after the surgical procedure. Patients undergoing a 
perioperative systemic treatment were re-staged and re-discussed in tumor 
board. 
Patients with locally advanced tumors (cT2 cN+ cM0, cT3/4 cNanycM0) underwent 
neoadjuvant or perioperative chemotherapy using platinum-based regimens. Four 
weeks after the end of the chemotherapy protocol the surgical procedure was 
scheduled. 
The two standard techniques used were esophageal resection with proximal 
gastrectomy and gastric-tube reconstruction via a right  thoraco-abdominal 
approach (RTA) and total gastrectomy through an open abdominal access 
(laparotomy) with a D2 lymphadenectomy as described before. 
 
Leading factors in the choice between the two surgical procedures were the 
localization of the tumor and its extension in mediastinum.  
Beside tumor charachteristics, the patient conditions and the preference of the 
surgeons were crucial in the surgical strategy. 
The assessment of the tumor charachteristics were performed through an 
endoscopy of the upper GI with ultrasonography.  
Additionally to the standard preoperative investigations as blood work, 
ECG, imaging of the lungs, the assessment of the perioperative risk (with 
particular attention to the possibility of standing a 2-3 hours long on-lung 
ventilation regimen) was based on the ASA classification and a 
measurement of the lung function, including a spirometry and an emogas 
analysis. 
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Pathological assessment 
 
All specimens were examinated in our pathologic institute. The pathological 
assessment was performed per standard guidelines and based on the 2010 
UICC TNM staging system (Sobin et al., 2011). 
In patients undergoing preoperative chemo- or radiochemotherapy the tumor 
regression was assessed per Becker et al (Becker et al., 2003). 
 
Lymph nodes were sent altogether with the main specimen and separated from 
the pathologist. The R status was assessed based on both the resection margins 
and the deepest layers of resection. An intraoperative pathologic examination of 
frozen sections of the resection margin was performed in order to avoid R1 
resections. 
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Follow Up 
All patients received a follow-up in our multidisciplinary out-patient clinic (tumor 
therapy center) according to the german guide-lines (Tab. 4) 
  Phisical Blood work 
Thorax             
X-Ray 
CT 
Abdome 
Uktrasound 
Gastroscopy 
3 Months X X X     X   
6 Months X X   X     X 
9 Months X X  X    X   
12 Months X X    X    X 
18 Months X X  X    X   
24 Months X X    X    X 
36 Months X X  X  X  X  X 
48 Monts X X  X  X  X  X 
60 Months X X  X  X X  X 
 
Tab. 4: Follow up schedule applied. 
 
In the presence of recurrence the case would be multidisciplinary evaluated and 
eventually a systemic or surgical treatment scheduled. 
The follow-up was performed in our center for at least 5 years postoperatively; 
afterward the patients were discharged into the care of their general practitioner. 
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Statistical Analysis 
 
Survival Analysis 
Differences in 30d mortality were investigated using the χ2-test. Survival analysis 
was performed using the Kaplan-Meier method for estimating survival 
probabilities and the log rank test for comparisons between patient groups. 
Median survival and hazard ratios were calculated and multivariate analysis of 
predictors was performed using a Cox proportional hazards model. p-values 
lesser than 0,05 were considered as statistically significant. 
Variables with a p<0.1 in univariable Cox regression analysis were entered into 
the multivariable model.  
 
 
Propensity score matching 
 
To correct for the sampling bias in the choice of the surgical procedure, we 
performed propensity score matching of prognostic variables and variables that 
could influence the choice of the procedure. Hereby 1:1 matching with a caliper of 
0.2 using the nearest-neighbour method as matching algorithm and logistic 
regression as estimation algorithm was employed (81). 
The statistical analysis was performed using SPSS Statistics V. 23 (IBM Corp, 
Ehningen, Germany) with a R plugin and R version 2.1.3 (R Core Team (2015). 
R: A language and environment forstatistical computing. R Foundation for 
Statistical Computing,Vienna, Austria.URL http://www.R-project.org/). SPSS was 
fitted with a custom dialog for propensity score matching (Propensit score 
matching in SPSS). 
 
 
The present study underwent the evaluation of our ethical commission and 
received a positive vote. 
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RESULTS 
 
 
 
Baseline characteristics (Tab. 4) 
 
270 patients were eligible for the study; 228 were male and 42 female; 91 
(33.7%) underwent RTA and 179 (66.3%) were treated by TH, average age was 
58.8±10.3 and 63.3±11 years respectively. Males received remarkably more 
often an RTA than females (35.96% vs. 18.42%). Neoadjuvant chemotherapy 
was administered in 191 cases, 83 (91.2%) patients undergoing RTA and in 108 
(60.3%) patients undergoing TH (p=0.001). An R0 resection was achieved in 69 
(75.8%) and 139 patients (77.7%), respectively (p=0.735). An extraluminal 
extension of the resection to adjacent organs/structures was necessary in 11 
(12.1%) patients undergoing RTA and 68 (38%) undergoing TH (p< 0.001). The 
mean esophageal extension of the tumor was 4.8 cm and 2.7 cm in the RTA vs. 
TH group (p=0.001). No significant difference in the number of resected lymph 
nodes was detected (RTA vs. TH: 27.9 vs. 26.4; p=0.244). 
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Parameter  RTA % TH % 
P pts. 91 33.7  179 66.3  
age (mean±SEM) 58.8±10.3 63.6±11.0 0.001*  
Sex 
Male 82 90.1  146 81.6  
0.067
§
  Female  9 9.9  33 18.4  
ASA 
1 73 80.2  107 59.8  
0.003
§
  2 12 13.2  52 29.1  
3 6 6.6  20 11.2  
neoadj. CTx 
No  8 8.8  71 39.7  
<0.001
§
  Yes 83 91.2  108 60.3  
UICC 2010 
0 6 6.6  5 2.8  
0.114
§
  
I 14 15.4  51 28.5  
II 29 31.9  55 30.7  
III 34 37.4  55 30.7  
IV 8 8.8  13 7.3  
R-status 
0 69 75.8  139 77.7  
0.735
§
  1 22 24.2  40 22.3  
R-status oral margin 
0 87 96.7  166 92.7  
0.277
+
  1 1 1.1  7 3.9  
X 2 2.2  6 3.4  
Grading  
1 1 1.1  2 1.1  
0.358
+
  
2 20 22.0  55 30.7  
3 62 68.1  115 64.2  
4 6 6.6  5 4.1  
X 2 2.2  2 1.1  
extralum. ext. 
No 80 87.9  111 62 
<0.001
§
  Yes 11 12.1  68 38 
esophageal ext. [cm]  mean (min-max) 4.8 (0-11) 2.7 (0-8) <0.001#  
resected LN mean (min-max) 27.9 (10-63) 26.4 (5-71) 0.244#  
*
T-test, 
§
Χ
2
-test, 
#
Mann-Whitney U-test,
+
Monte-Carlo significance  
    
Tab. 5: Baseline characteristics: 270 patients with AEGII were surgically 
resected. Of these, 91 patients (33.7 %) received right thoraco-abdominal 
resections (RTA) and 179 patients (66.3%) underwent transhiatal abdominal 
resection (TH) 
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Fig. 12: 91 RTA were performed and 179 TH 
 
 
Fig. 13: In the investigated cohort (270 patients) 228 subjects were male and 42 
were female.  
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Males received remarkably more often an RTA than females (35.96% vs. 
18.42%). 
 
Fig. 14: Demography of ASA Score in our patients cohort 
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Fig. 15: Neoadjuvant chemotherapy was administered in 191 cases, 83 (91.2%) 
patients undergoing RTA and in 108 (60.3%) patients undergoing TH (p=0.001). 
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Fig. 16: Most of our patients presented a stage II tumor, the staging was slightly 
worse in the cohort undergoing TH 
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Fig. 17: the achievement of an R0 resection was relatively low, mostly due to the 
infiltration of the esophageal wall. 
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Morbidity and mortality (Tab. 6) 
 
 
The RTA group showed a higher complication rate (34.1% vs. 24.6%; p=0.006), 
mostly due to anastomotic leaks (4.4% vs. 2.8%) and wound infections (12.1% 
vs. 1.7%). 
This, however, did not translate into a higher 30 day mortality rate, which was 
1/91(1.1%) in the RTA group and 8/179(4.5%) in the TH group (p=0.134). 
 
parameter  RTA % TH % 
p 
pts. 91 33.7  179 66.3  
30d mortality 
No 90 98.9  171 95.5  
0.134
#
  Yes 1 1.1  8 4.5  
complications  
None 60 65.9  135 75.4  
0.006
+
  
anast. Leak 4 4.4  5 2.8  
wound inf. 11 12.1  3 1.7  
intraabd. abscess/peritonitis 1 1.1  8 4.5  
other postoperative 8 8.8  15 8.4  
Medical 7 7.7  13 7.3  
§
Χ
2
-test, 
#
Fisher's exact test, 
+
Monte-Carlo significance  
     
Tab. 6: Clinical outcomes: 30-day mortality and postoperative complications 
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Recurrence (Tab. 7) 
 
 
The RTA group presented a higher recurrence rate (33%), which was mostly 
systemic. Recurrence in the TH group was observed in 23.5% of cases, which 
occurred mostly locally (p=0.025). 
 
parameter  RTA % TH % 
p 
pts. 91 33.7  179 66.3  
recurrence  
None 61 67.0  137 76.5  
0.025
§
  
R1/progression 4 4.4  13 7.3  
local  3 3.3  11 6.1  
LYM 7 7.7  5 2.8  
HEP 4 4.4  2 1.1  
PER 2 2.2  5 2.8  
OTH 3 3.3  3 1.1  
Multiple 7 7.7  3 1.1  
§
Monte-Carlo significance  
      
Tab. 7: Recurrence: Localizations 
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Survival 
 
 
As shown in the following graphics, patients undergoing TH showed a statistically 
insignificant better outcome in terms of overall-survival (OS) (p=0.448). Median 
OS was 34.4±6.2 months for patients undergoing RTA and 48.6±10.7 months for 
the TH group (Fig. 18). 
 
Fig. 18: Overall Survival (Median OS: RTA: 34.4±6.2 months;  TH: 48.6±10.7 
months), p=0.448 
 
Disease free survival (DFS) was longer in the TH group, marginally not reaching 
significance-level (Median DFS for RTA vs. TH: 22.0±3.6 months vs. 43.0±7.2 
months, p=0.085) (Fig. 19). 
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Fig. 19 Disease free survival (Median DFS: RTA: 22.0±3.6 months; TH: 43.0±7.2 
months), p=0.085 
 
Conversely the outcomes in terms of OS in patients with a tumor extending 
higher than 3 cm into the thoracic esophagus was better when treated by RTA 
than with TH. This difference, however, again did not reach significance-level 
(esophageal extension ≤3cm: median OS RTA vs. TH: 58,3±16,6 months vs. 
25,7±3,4 months, p=0.064; esophageal extension >3cm: median OS RTA vs. TH: 
35,9±9,4 months vs. 37,5±11,9 months, p=0.592) (Fig. 20a and b). 
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Fig. 20a: Esophageal extension <3cm: median OS RTA vs. TH: 58.3±16.6 
months vs. 25.7±3.4 months, p=0.064 
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Fig 20b: esophageal extension >3cm: median OS RTA vs. TH: 35.9±9.4 months 
vs. 37.5±1.9 months, p=0.592 
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Prognostic factors (Tab. 9 and Fig. 21-23) 
 
Age (p=0.047), ASA score (p=0.025), R-status (p<0.001) and UICC stage 
(p<0.001) were prognostic factors in univariable Cox regression analysis, while 
grading marginally failed to reach significance-level (p=0.057).  
 
Parameter  RTA % TH % 
P pts. 59 50  59 50  
age (mean±SEM) 59.0±1.4 60.8±1.6 0.552*  
Sex 
Male 53 89.8  48 81.4  
0.190
§
  Female  6 10.2  11 18.6  
ASA 
1 48 81.4  44 74.6  
0.132
§
  2 5 8.5  12 20.3  
3 6 10.2  23 5.1  
neoadj. CTx 
No  7 11.9 4 6.8  
0.342
§
  Yes 52 88.1  55 93.2  
UICC 2010 
0 4 6.8  2 3.4  
0.814
§
  
I 12 20.3  14 23.7  
II 16 27.1  19 32.2  
III 23 39.0  19 32.2  
IV 4 6.8  5 8.5  
R-status 
0 46 78  43 72.9  
0.521
§
  1 13 22  16 27.1  
Grading  
1 1 1.7  0 0  
0.705
+
  
2 17 28.8  19 32.2  
3 37 62.7  35 59.3  
4 2 3.4  4 6.8  
X 2 3.4  1 1.7  
extralum. ext. 
No 49 83.1  47 79.7 
0.636
§
  Yes 10 16.9  12 20.3 
esophageal ext. [cm]  mean (min-max) 3.97 (0-11) 3.780 (0-8) 0.983#  
resected LN mean (min-max) 28.2 (10-63) 26.79 (5-56) 0.634#  
*
T-test, 
§
Χ
2
-test, 
#
Mann-Whitney U-test,
+
Monte-Carlo significance  
    
Tab. 8. Baseline characteristics after propensity score matching: 118 patients 
with AEGII were matched (59 from each cohort). 105 patients undergoing TH 
were unmatched, 27 undergoing RTA were unmatched. No patient was 
discarded. 
  
 Page 59 
 
 
After these factors were entered into the multivariable Cox model, age, ASA-
class and higher UICC stage were identified as independent negative prognostic 
factors for OS. 
 
  
Hazard 
Ratio 
95% CI Significance 
p-value 
  
lower Upper 
Age  (yrs.) 1.020 1.005 1.036 0,017 
ASA 
 I 
 
    
0,021 II 0.555 0.367 0.840 
III 0.835 0.466 1.494 
UICC 
 0 
 
    
<0,001 
I 3.334 0.447 24.855 
II 7.283 1.000 53.043 
III 15.471 2.141 111.777 
IV 60.513 7.936 461.438 
 
Tab. 9: Independent prognostic factors (multivariable Cox analysis): Age, ASA 
and UICC stag 
 
After propensity score  matching (PSM) for ASA, age, UICC stage, R-status, 
grading, extent of esophageal involvement, neoadjuvant chemotherapy and 
postoperative complications there was no difference in OS (RTA: 37.5±13.6 
months TH: 35.7±6.5 months , p=0.669) and DFS (RTA: 27.0±7.9 months TH: 
24.0±6.5 months , p=0.535). 
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Fig. 21a: Propensity score matching to control for prognostic confounders: 
age>60 years, higher ECOG status, higher UICC stage and R2 resection were 
identified as independent negative prognostic factors for overall survival. 
 
 
age 
UICC stage 
R-status 
esoph. ext. 
pre-OP Tx 
organ res. 
complication
. 
 Page 61 
 
 
Fig. 21b: Distribution of propensity scores before and after matching 
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Fig. 22: OS – matched patients (n=62 vs.62). Median OS: RTA: 37.5±13.6 
months; TH: 35.7±6.5 months, p=0.669 
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Fig. 23: DFS after matching DFS – matched patients (n=62 vs.62). Median DFS: 
RTA: 27.0±7.9 months; TH: 24.0±6.5 months, p=0.535. 
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DISCUSSION 
 
In order to establish if there is a difference in oncological accuracy between the 
two techniques we compared the results of the two cohorts in terms of survival, 
recurrence and extension of the intrathoracic resection and of the lymph node 
dissection. 
 
 
Survival 
 
Based on our results, it appears that both surgical techniques are comparable 
from an oncologic point of view, both yielding satisfactory surgical outcomes in a 
high volume center.  
Regarding differences in the extent of lymph node dissection, this study could not 
detect a statistically significant difference in outcome (neither OS nor DFS) 
between RTA and TH. 
Conversely, OS in patients with a tumor extending higher than 3 cm into the 
thoracic esophagus was better when treated by RTA than with TH.  
It has to be stated that this result might be influenced by a selection bias. In fact it 
is possible that the choice of performing a RTH rather than TH could be 
influenced by a better physical condition of the respective patient. 
A study including AEG I, II and III (Hosoda et al., 2015) obtained results similar to 
this analysis, without significant difference between RTA and TH.  Main 
predictors for poor survival were (y)pT3-4 and N3 stage stages, R1 or R2 and the 
absence of splenectomy. Thoracotomy could also be identified as a negative 
prognostic factor. 
Kurokawa et al compared the 10 years follow-up data of 85 patients undergoing 
LTA vs. 82 undergoing TH for EJA type II and III in a multicentre prospective 
randomized phase 3 trial in 2015 (Kurokawa et al., 2015). The results showed no 
advantage in terms of OS or recurrence rate for LTA. Morbidity and mortality 
were, however, significantly worse after LTA. The same conclusion was reached 
by Carboni et al (Carboni et al., 2008). 
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Conversely (Omloo et al., 2007) Omloo et al. compared the two surgical 
approaches on 220 patients with EJA I and II and revealed a survival benefit after 
performing RTH but only for EJA I. 
 
The low rate of R0 resections achieved in our study has to be noticed (75,8% and 
77,7% respectively in RTA and in TH groups). This could be explained through 
the quite advanced stage of the disease in our cohort of patients and the fact that 
margin-positivity predominantly occurred in the third dimension, where radicality 
is limited at the aorta and no frozen sections can be obtained during surgery.  In 
fact the R0 rate at the oral margin exceeded 90% in both groups (96,7% and 
92,7% respectively in RTA and TH groups). 
 
Recurrence 
 
The RTA group presented a higher recurrence rate (33%), which was mostly 
systemic. Recurrence in the TH group was observed in 23.5% of cases, which 
occurred mostly locally (p=0.025). 
This finding contradicts the common belief that the more invasive RTA is justified 
by the achievement of better oncological results. Nevertheless we cannot even 
state that TH guarantees better oncological results, since and UICC stage was 
slightly worse in the RTA cohort. 
 
A recently published meta-analysis (Heger et al., 2017) evalued eight studies 
comparing the surgical and oncological outcomes of cardia adenocarcinoma 
patients undergoing trans-thoracic resection vs. transhiatal resection. In this 
study no results on recurrence rate were disclosed therefore we can hardly 
compare our results.  
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Intrathoracic extension 
One of the paramount questions for the choice of the operative procedure in EJA 
is whether it is technically possible to obtain a safe oral margin by performing a 
TH and if there is an intrathoracic extension beyond which the probability to 
achieve an R0 resection is lower? The studies of Mine et al. (87) proposed a 
cutoff of 2 cm for esophageal invasion. Kurokawa et al., reached the same 
conclusion in a multicentre prospective randomized phase III trial (Kurokawa et 
al., 2015). Another study shows that a reasonable cut-off for the RTA vs TH could 
be an intra-thoracic extension greater than 3 cm, both in terms of survival and R0 
resection achievement (mine et al., 2013). Sasako et al. evaluated the OS and 
the comorbidity of left thoraco-abdominal resection (LTA) vs. TH as resection for 
AEG II and III in an RCT on 302 patients, showing that LTA cannot be justified to 
treat EJA II and III if the length of esophageal invasion is 3 cm or less (Sasako et 
al., 2006). In fact in order to oncologically completely remove these tumors the 
esophageal resection should be extended very high into the thorax, a procedure 
which could be more safely and completely performed through a right 
thoracotomy. 
The findings of our analysis are in line with these results. As a matter of fact, 
according to our findings, patients with an intra-thoracic extension of the tumor of 
more than 3 cm don´t seem to have a survival benefit from TH compared to RTA, 
as shown in Figure 3. 
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Lymph Node Dissection 
  
Our results showed no significant difference in the number of resected lymph 
nodes (LN). This could be explained by the fact that LN-dissection in the D2-
compartment was routinely performed in both groups. 
However, it remains elusive if there were considerate differences in lower 
mediastinum node dissection, as there is no date on this specific issue. This is 
explicated by the fact that an “en-bloc” resection is considered mandatory and 
therefore the lymph nodes were left attached to the specimen without separate 
examination neither by the surgeon nor by the pathologist. 
 
Nevertheless the clinical therapeutic and diagnostic role of the exact extent of 
lymphadenectomy in EJA is still to be clarified.  
 
A study by Okholm et al stated that the dissection of local lymph nodes offers a 
significant therapeutic benefit, because the most frequent infiltrated lymph nodes 
(LN) are located in the nearest regional LN stations; furthermore the survival 
decreases as the metastasis become more distant (Okholm et al., 2014). 
Another study by Yamashita et al (Yamashita et al., 2011) suggested that a clear 
anatomic distinction of EJA could provide insight on the appropriate extent of the 
lymphadenectomy. Nevertheless, the paracardial and the lesser curvature LNs 
must be dissected in order to achieve a proper staging and cure. The same 
conclusion was reached by Hasegawa et al (Hasegawa et al., 2013), stating that 
the involvement of further LN-stations implicates the existence of micro-
metastasis beyond the limitations of the surgical field, which could be more safely 
controlled by systemic CTx. 
Goto et al (Goto et al., 2014) detected a higher N-stage in Siewert type II rather 
than type III, probably due to more advanced pT-stages. These results underline 
the importance of -abdominal lymphadenectomy, especially of the lower 
perigastric LN. The actual impact of lower mediastinal lymphadenectomy could 
not be properly investigated in this analysis. 
The minimally required number of LNs to be dissected is still considered elusive. 
A retrospective, exploratory study by Sisic et al (Sisic et al., 2013) evaluated the 
number of metastatic LNs comparing the oncological outcome in 316 EJA I and II 
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patients. Their results showed a high prognostic relevance of the number of 
dissected LNs. RTA ensures a better lymphadenectomy of the lower 
mediastinum, but no resection of the LNs at the greater stomach curvature and 
the pylorus. Conversely the standard lymphadenectomy in TH is a D2 
lymphadenectomy including the LN stations #19, #20, #110 and #111 (Hosokawa 
et al., 2014), which allows for an improved intraabdominal lymphadenectomy, but 
cannot be  similarly radical in the mediastinum. 
Many efforts have been made in order to assess a priority in the way 
lymphadenectomy during resection of EJA should be performed. 
In 2011 Yamashita et al. (Yamashita et al., 2011) published a study comparing 
the extent and location of nodal dissection to assess the survival benefit of 
extensive lymphadenectomy. A low incidence of LN-metastasis at the greater 
curvature was detected, and the index of estimated survival benefit from the 
dissection of stations #4d, #4sb and #6 in AEG II tumors was zero. 
Hosokawa et al. reviewed the recurrence pattern of EJA after radical resection 
(Hosokawa et al., 2014). The most frequent routes of tumor cell dissemination in 
EJA II was hematogenous (lymphatic in EJA I and disseminative in EJA III).  
Multivariate analysis revealed that mediastinal LN-metastases were an 
independent prognostic indicator of poor rence-free survival. The recurrence rate 
in patients with mediastinal LN-metastases at the time of surgery was 100%. 
These data seem to suggest that mediastinal lymph node dissection may be 
effective for local control, but may not significantly improve prognosis. 
As these data were not available for this analysis, it has to be stated that this is a 
major limitiation. Due to the heterogeneous data in the literature, further study on 
the role of optimal lymph node dissection for true EJA are required. 
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Morbility and mortality 
 
In our study the RTA group showed a higher complication rate (34.1% vs. 24.6%; 
p=0.006), mostly due to anastomotic leaks (4.4% vs. 2.8%) and wound infections 
(12.1% vs. 1.7%). This was expected, because of the higher invasiveness of the 
transthoracic approach. However the higher complication rate did not influence 
the 30 day mortality rate, which was 1/91(1.1%) in the RTA group and 
8/179(4.5%) in the TH group (p=0.134). 
This data are comparable with the meta-analysis performed by Heger et al. 
(Heger et al., 2019) which showed a significantly lower rate of postoperative 
morbidity at comparable oncological and surgical outcomes and postoperative 
short-term mortality. 
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Propensity score matching 
 
One of the main aims of our study was to achieve the best possible comparability 
in the two patients’ cohorts in order to better define the actual impact of the 
surgical technique on the oncological and surgical outcome. PSM is a statistical 
method applied to reduce possible selection-bias in observational/non-
randomized studies, which was initially proposed by Rubin and Rosenbaum in 
1983, ruling out confounders in non-randomized studies. Ruling out the 
differences among the patients analyzed here propensity score (PS) matching 
analysis was applied as statistical method to eradicate the differences in baseline 
characteristics between the two treatment groups. 
It is widely accepted that the best study model is a completely randomized 
experiment (Pattanayak et al., 2011, Heinze et al., 2011), where the assignment 
to treatment is blind and not at all influenced by the characteristics of patients. 
Only in this way the balance on background measurements such as age, sex and 
medical histoly can be achieved. 
This kind of study is for obvious reasons (logistics, economics and above all, 
ethics) not always applicable. In these cases an observational study will be 
performed, leading to a bias in the assignment of the treatment. For example if a 
procedure is very risky, most likely elderly patients as much as patients with 
higher perioperative risk will more often receive the control procedure, i.e. the 
control group will have a much higher incidence of elderly or ill subjects. 
To help balance this bias, patients will be subclassified based on their 
characteristics (covariates).  
The propensity score is defined as the propability that a subject will receive a 
specific treatment based on the observed covariates (Austin et al., 2009). In an 
observational study patients are grouped based on their similar characteristics 
and the propensity score may differ from group to group, but it will be the same 
within the patients belonging to the same group. 
By comparing patients with similar estimated propensity scores, an observational 
study can resemble a randomized experiment (Pattanayak et al., 2011). 
There are three types of statistical analyses based on the propensity score (96): 
- Propensity score matching  
- Stratification on the propensity score 
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- Covariate adjustment using the propensity score. 
 
We, as many other researchers, preferred the PSM method because it seems to 
be able to eliminate a greater degree of treatment selection bias, it can compare 
baseline characteristics between treated subjects and controls, moreover it does 
not require the specification of the outcomes model and it allows for estimation of 
risk differences and relative risk. 
On the other side PSM presents as a limitation the reduction in sample size due 
to omission of unmatched subjects. 
  
There are more possible algorithms: 
- Greedy matching: subjects in the treatment cohort will be matched with 
the next control subject in the same PS even if it would be a better match 
to a subsequently considered treated subject. 
- Optimal matching: pairs of treated and control subjects are formed so as 
to minimize the differences within pairs. 
- 51 matching: a greedy matching is applied in several phases in 
which treated-cohort pairs will be matched on the first 5 digits of PS, then 
on the first four digits, and so long until they will be matched on the first 
digit. 
 
After PSM, the baseline characteristics of our cohort were well balanced (Fig. 
4a). In multivariate Cox analysis the impact of the surgical technique and the 
extent of lymphadenectomy were not as pronounced as the more “classical” 
factors as age, ASA and tumor stage. Conclusively, survival analysis after PSM 
revealed, that there were no differences in OS when the patient cohorts were 
balanced for possible confounders.  
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Limitations 
 
Single center retrospective analysis: 
The analysis was done in a single center cohort and possible selection bias seem 
to be present and not controlled by PSM.  
Although PSM is well accepted as method to eradicate selection bias (Kim et al., 
2916), there are some unmeasured factors, such as for example the biological 
/genetical differences and the influence of the surgeon’s expertise on outcome.  
 
 
Lymph node harvesting technique: 
 
As previously discussed we performed the lymph nodes harvesting „en bloc“, id 
est without separating the nodes from the organ. This technique, established in 
the west world since UICC 1999 does not allow the assessement oft he station to 
which the lymph nodes belong. 
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CONCLUSION 
 
The present analysis could not detect a statistically significant difference between 
RTA and TH from the oncologic point of view; unexpectedly RTA was not 
associated with higher morbidity and mortality. 
Conclusively RTA for Siewert Type II EJA should be preferred whenever the oral 
tumor margin cannot be safely reached via a transhiatal approach. Hereby an 
esophageal extension of the tumor >3cm seems to be a reasonable cutoff. 
This cutoff should be further tested and proved; in this regard a prospective, 
randomized, controlled, multiscentric trial is scheduled. 
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